CRIS Current Research Information System

BACCARANI, MICHELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 23.526
EU - Europa 17.515
AS - Asia 6.796
AF - Africa 1.118
Continente sconosciuto - Info sul continente non disponibili 73
SA - Sud America 44
OC - Oceania 21
Totale 49.093
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 23.453
GB - Regno Unito 5.776
SE - Svezia 3.089
CN - Cina 2.582
VN - Vietnam 2.219
DE - Germania 2.168
IT - Italia 1.978
UA - Ucraina 1.021
IN - India 989
FR - Francia 716
IE - Irlanda 716
RU - Federazione Russa 642
ZA - Sudafrica 406
EE - Estonia 391
TG - Togo 370
SG - Singapore 307
CH - Svizzera 266
JP - Giappone 197
JO - Giordania 196
BG - Bulgaria 170
CI - Costa d'Avorio 137
FI - Finlandia 126
BE - Belgio 109
NG - Nigeria 107
IR - Iran 89
GR - Grecia 84
SC - Seychelles 78
HR - Croazia 72
CA - Canada 69
EU - Europa 66
TR - Turchia 54
NL - Olanda 39
AT - Austria 37
LB - Libano 31
PL - Polonia 31
BR - Brasile 22
RO - Romania 20
HK - Hong Kong 19
MY - Malesia 19
AU - Australia 18
KR - Corea 18
UZ - Uzbekistan 18
ES - Italia 17
CZ - Repubblica Ceca 15
CL - Cile 13
TW - Taiwan 11
ID - Indonesia 8
A2 - ???statistics.table.value.countryCode.A2??? 7
BD - Bangladesh 7
IL - Israele 7
PH - Filippine 7
EG - Egitto 6
TN - Tunisia 6
PT - Portogallo 5
RS - Serbia 5
AE - Emirati Arabi Uniti 4
AR - Argentina 4
NO - Norvegia 4
SA - Arabia Saudita 4
DK - Danimarca 3
IQ - Iraq 3
KE - Kenya 3
NZ - Nuova Zelanda 3
AL - Albania 2
BA - Bosnia-Erzegovina 2
EC - Ecuador 2
HU - Ungheria 2
MK - Macedonia 2
ML - Mali 2
MX - Messico 2
PE - Perù 2
PK - Pakistan 2
QA - Qatar 2
SK - Slovacchia (Repubblica Slovacca) 2
UG - Uganda 2
BO - Bolivia 1
BS - Bahamas 1
BY - Bielorussia 1
CR - Costa Rica 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LT - Lituania 1
LV - Lettonia 1
MA - Marocco 1
MD - Moldavia 1
SI - Slovenia 1
TH - Thailandia 1
Totale 49.093
Salva come PNG Salva come JPEG
Città #
Southend 5.272
Fairfield 3.338
Chandler 2.428
Ashburn 1.992
Woodbridge 1.752
Houston 1.563
Seattle 1.549
Wilmington 1.533
Dong Ket 1.340
Cambridge 1.206
Ann Arbor 1.200
Princeton 1.075
Dublin 711
Jacksonville 629
Nanjing 510
Westminster 470
Padova 460
Lomé 370
Beijing 347
Bologna 286
Berlin 267
Saint Petersburg 237
Jinan 230
New York 229
Bern 219
Shenyang 219
Singapore 203
San Diego 198
Amman 196
Turin 196
Sofia 170
Bremen 167
Hebei 166
Nanchang 158
Boardman 155
Tokyo 153
Changsha 146
Abidjan 137
Medford 132
Helsinki 121
Milan 117
Jiaxing 115
Mülheim 111
Redmond 107
Abeokuta 106
Brussels 105
Redwood City 98
Florence 97
Tianjin 97
Falls Church 87
Norwalk 80
Haikou 73
Mahé 72
Zhengzhou 72
Des Moines 65
Dearborn 64
Hangzhou 58
Ningbo 50
Olalla 48
Taizhou 48
Verona 48
Los Angeles 44
Taiyuan 43
Toronto 42
Istanbul 40
Lanzhou 40
Rome 40
Guangzhou 39
London 37
Mountain View 35
Bühl 34
Andover 33
Zanjan 32
Kunming 31
Washington 31
Leawood 28
Paris 28
Frankfurt am Main 25
Hyderabad 24
Vienna 22
Sacramento 19
San Venanzo 18
Fuzhou 17
Lausanne 17
Pune 17
Chicago 16
Kuala Lumpur 16
Phoenix 16
São Paulo 16
Frankfurt Am Main 15
Monmouth Junction 15
San Francisco 15
Tappahannock 15
Fremont 14
Groningen 14
Kuban 14
Menlo Park 12
Grafing 11
Hefei 11
Henderson 11
Totale 34.395
Salva come PNG Salva come JPEG
Nome #
Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia 323
Application of the whole-transcriptome shotgun sequencing approach to the study of Philadelphia-positive acute lymphoblastic leukemia 262
Acute graft-versus-host disease and steroid treatment impair CD11c+ and CD123+ dendritic cell reconstitution after allogeneic peripheral blood stem cell transplantation. 248
A polymorphism in the chromosome 9p21 ANRIL locus is associated to Philadelphia positive acute lymphoblastic leukemia 247
18F-FDG PET early after radiotherapy in lymphoma patients. 228
A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. 226
B-cell acute lymphoblastic leukemia as evolution of a 8p11 myeloproliferative syndrome with t(8;22)(p11;q11) and BCR-FGFR1 fusion gene. 214
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 210
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia 210
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. 210
Prolonged low-dose azacitidine schedule in high-risk MDS patients: Hematologic and molecular response 197
Binding Mode Of The Novel Dual SRC and ABL Inhibitor SKI-606 To The BCR-ABL Kinase As Predicted By Molecular Docking Studies 195
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis 192
A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. 187
Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy 184
c-MYC oncoprotein dictates transcriptional profiles of ATP-binding cassette transporter genes in Chronic Myelogenous Leukemia CD34+ hematopoietic progenitor cells 182
Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase. 182
Generation of dendritic cells from positively selected CD14+ monocytes for anti-tumor immunotherapy. 180
CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients. 177
Allotransplant in relapsed or refractory aggressive T-cell lymphomas: retrospective monocentric analysis of 14 patients 174
A phase 2 trial of fludarabine and mitoxantrone chemoterapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma 171
Dual Src/Abl inhibitor SKI-606 binding mode in BCR-ABL kinase hypothesized on the basis of molecular docking studies 169
Advances and potential treatment for Philadelphia chromosome-positive adult acute lymphoid leukaemia. 168
VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly. 168
Bleeding in essential thrombocythaemia: a retrospective analysis on 565 patients 167
Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. 166
A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. 166
Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications. 164
Complete paraplegia after nelarabine treatment in a T-cell acute lymphoblastic leukemia adult patient. 164
Molecular response to imatinib in late chronic-phase chronic myeloid leukemia 162
Prediction of response to primary therapy with thalidomide-dexamethasone (thal-dex) for newly diagnosed multiple myeloma by gene expression profiling (gep) 161
Denaturing-HPLC-based assay for detection of ABL mutations in Chronic Myeloid Leukemia patients resistant to Imatinib 160
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia 160
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients. 158
Alemtuzumab in the treatment of relapsed acute lymphoid leukaemia. 158
First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients. 157
Advances in the treatment for haematological malignancies. 157
Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR) 157
Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas 156
ARF Loss, a Negative Prognostic Factor in Philadelphia-Positive Acute Lymphoblastic Leukemia, May Be Efficiently Overcome by the Small Molecule MDM2 Antagonist RG7112 156
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line 153
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. 153
Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells. 151
Identification of a novel t(1;9)(q11;q34) in acute myelocytic leukemia 148
Gene expression profiling of normal and malignant CD34-derived megakaryocytic cells. 148
Higher numbers of blood CD14+ cells before starting conditioning regimen correlate with greater risk of acute graft-versus-host disease in allogeneic stem cell transplantation from related donors. 148
Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr–Abl mutations and mutational analysis 147
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: Molecular cytogenetic characterization and influence on TKIs therapy 147
CHK2 drives late G1/early S phase arrest of clonal myeloid progenitors expressing the p210 BCR-ABL tyrosine kinase in response to STI571 147
Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes. 146
Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. 146
Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome. 145
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. 145
Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. 145
Clonal Effect Of Lenalidomide On Akt Activation In Low-Risk MDS Patients With Del(5q) 145
Complete remission upon bortezomib-dexamethasone therapy in three heavily pretreated multiple myeloma patients relapsing after allogeneic stem cell transplantation. 145
Acute promyelocytic leukemia with amplification of PML-RARalpha rearrangement:clinical implications 144
Cryotherapy in the prevention of oral mucositis in patients receiving low-dose methotrexate following myeloablative allogeneic stem cell transplantation: a prospective randomized study of the Gruppo Italiano Trapianto di Midollo Osseo nurses group. 143
AZACITIDINE IN MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF LONG-RESPONDER PATIENTS 143
Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study 143
BCR-ABL1 transcript detection in patients with Philadelphia-positive Acute Lymphoblastic Leukemia (ALL) using a new and high sensitive nanofluidic method 143
Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients. 142
Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma. 142
Ascorbic acid inhibits antitumor activity of bortezomib in vivo 141
AZACITIDINE FOR HIGH RISK MYELODYSPLASTIC SYNDROMES. RETROSPECTIVE EVALUATION OF TWO DIFFERENT DOSING SCHEDULES 138
High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma: the Bologna experience 137
Immune therapy of chronic myelogenous leukemia. 136
Successful treatment of severe hemorrhagic cystitis with selective vesical artery embolization. 136
Flai (fludarabine, cytarabine, idarubicin) plus low-dose gemtuzumab ozogamicin as induction therapy in cd33-positive aml: Final results and long term outcome of a phase ii multicenter clinical trial 136
Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. 134
Association of essential thrombocythemia and non-Hodgkin lymphoma: a single-centre experience 134
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib 134
First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia 134
Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response, a study of the GIMEMA CML WP. 134
Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. 133
Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation. 133
MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia 133
Decreased expression of indoleamine 2,3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia 132
Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. 131
Effects of granulocyte colony stimulating-factor in a rat model of acute liver injury. 131
Analisi di polimorfismi in geni coinvolti nel ciclo dei folati come determinanti di suscettibilità a leucemia mieloide cronica. 130
Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib. 130
Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results. 130
Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL) patient with breast infiltration 130
Anti-leukemic and anti-GVHD effects of campath-1H in acute lymphoblastic leukemia relapsed after stem-cell transplantation. 130
IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia. 130
A germline polymorphism in the ANRIL (CDKN2BAS) locus is associated with susceptibility to Philadelphia-positive acute lymphoblastic leukemia (ALL) 130
NUCLEOFECTION IS AN EFFICIENT NON-VIRAL TRANSFECTION TECHNIQUE FOR HUMAN BONE MARROW-DERIVED MESENCHYMAL STEM CELLS. 130
Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients 128
Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. 128
Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. 127
Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. 126
Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcripts 126
First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma. 125
A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma. 125
Backtracking BCR-ABL1 Mutants in Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Relapsing on Tyrosine Kinase Inhibitors with Deep Sequencing: Implications for Routine Mutation Testing 125
Extracellular nucleotides are potent stimulators of human hematopoietic stem cells in vitro and in vivo. 125
Successful resumption of epoetin alfa after rituximab treatment in a patient with pure red cell aplasia. 125
The extracellular nucleotide UTP is a potent inducer of hematopoietic stem cell migration. 124
Computed tomographic pulmonary angiography for diagnosis of invasive mold diseases in patients with hematological malignancies 124
Totale 15.667
Salva come PNG Salva come JPEG
Categoria #
all - tutte 119.969
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 119.969
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202012.449 0 396 128 982 1.507 1.415 1.752 1.837 1.998 925 614 895
2020/20217.853 1.421 571 165 320 252 421 172 436 714 432 467 2.482
2021/20229.676 1.049 266 732 966 913 622 191 620 358 759 1.637 1.563
2022/202310.280 1.243 1.576 584 1.343 677 817 370 535 1.621 236 810 468
2023/20242.533 152 424 151 247 209 602 152 134 87 153 99 123
2024/2025288 284 4 0 0 0 0 0 0 0 0 0 0
Totale 50.257